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Abstract 
Jeremy Martinson, PhD 
 
 
Relationship Between Single Nucleotide Polymorphisms and Severe Dengue in a 
Brazilian Population 
 
Dzigbordi Kamasa-Quashie, MPH 
University of Pittsburgh, 2020 
 
 
Abstract 
 
Dengue virus has become one of the most important arboviral diseases of today. With 
nearly half of the global population at risk, this infectious disease carries great significance. The 
aim of this study was to determine the relationship between 18 single nucleotide polymorphisms 
(SNPs) and severe dengue in a population from Recife, Brazil. The SNPs of interest are as follows: 
TLR8 rs17256081, IFNG rs2069718, IFNG rs2069727, IRF1 rs2070729, OAS2 rs2072137, OAS2 
rs2072138, OAS3 rs2240188, MX1 rs3737399, VEPH1 rs3911403, IRAK4 rs4251580, CLEC4C 
rs17199006, PLCE1 rs3740360, MRC1 rs606231248, MRC1 rs2296414, RNASEL rs486907, 
OASL rs3213545, MX1 rs7277299, and MICB rs3132468. A total of 450 DNA samples were 
pulled from two studies—a cohort study of dengue patients and a yellow fever vaccine cohort. 
Sample concentrations were tested using the Nanodrop 1000 Spectrometer. The concentrations of 
all samples were between 10-100 ng/L, per the laboratory technician’s request. Samples were 
transported to the University of Pittsburgh’s Genomic Core Research Laboratory for genotyping 
using the iPlex MassARRAY system and results were analyzed using Microsoft Excel and R 
statistical software. Of the 18 SNPs, statistically significant results were observed for OAS2 
rs2072137, OAS3 rs2240188, PLCE1 rs3740360, and MX1 rs7277299. For OAS2 rs2072137, the 
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CC genotype was shown to be significantly associated with severe dengue (OR=2.10, P=0.01). 
The CC genotype associated with OAS3 rs2240188 also appears to influence disease severity 
(OR=1.96, P=0.02). For PLCE1 rs3740360, calculations reveal a significant association between 
the AA genotype and severe dengue (OR=2.28, P=0.03). The last notable result was found in MX1 
rs7277299 (OR=5.33, P=0.02) where the CC genotype was also significantly associated with 
severe disease. Though this is one of the largest dengue-related gene association studies, further 
research is necessary to validate the findings. The increasing burden of dengue disease signifies 
the public health importance of this research—to contribute to the advancement of dengue 
research, vaccine development, therapeutic strategies, and diagnostic tools. 
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1.0 Introduction 
The purpose of this project is to understand whether or not certain genetic polymorphisms 
increase an individual’s risk of developing severe dengue. The single nucleotide polymorphisms 
(SNPs) in question were all selected from various studies that suggest an increased risk of severe 
dengue exists. The subset of DNA samples used in this project belong to a larger dengue study which 
was conducted at the Aggeu Magalhães Research Center by researchers in the Department of 
Virology in Recife, Brazil. Dengue cases are stratified into three categories—dengue fever, 
complicated dengue and dengue hemorrhagic fever. The controls are enrolled patients who were 
determined to be dengue free and dengue negative volunteers from a separate yellow fever vaccine 
cohort.  
The concentration of each sample was tested prior to the genotyping process. Genotyping 
was performed on 450 samples by the University of Pittsburgh’s Genomics Research Core 
Laboratory. Results were analyzed using Microsoft Excel and R statistical software. Two principal 
component analysis plots were created to visualize a relationship between SNPs and disease status. 
Hardy-Weinberg equilibrium (HWE) testing was performed to compare observed and expected 
allele and genotype frequencies, followed by significance testing using chi-squared calculations. 
Odds ratios were performed to uncover significant associations between genetic makeup and severe 
dengue. To my knowledge, this is the most comprehensive genetic analysis of these samples.  
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2.0 Background 
2.1 Dengue 
Flaviviruses are characterized by positive, single-stranded RNA genomes (2). Other 
commonly known viruses in this family include West Nile virus, Japanese encephalitis and Yellow 
Fever (2). These viruses are generally found in ticks and mosquitoes (2). Though the Aedes aegypti 
mosquito is the principal vector for dengue, research shows that Aedes albopictus is also capable of 
transmitting the virus, albeit less efficient (3). A. aegypti originated in Africa before it was spread 
throughout the world via trade and war (4). Its ability to adapt to urban environments, daytime 
feeding behavior, and preference for indoors contributes to its efficiency (4).  
The cycle of viral transmission between human and mosquitos is contingent upon the 
frequency of human interaction, like most infectious diseases. Mosquitos contract the virus after 
feeding on an infected host. Viral replication occurs in the mosquito’s midgut before spreading to 
secondary tissues (5). The extrinsic incubation period, the time between infection and transmission 
to a new host, lasts for roughly 8-12 days in adequate conditions—25-28 C (5). Once infected, 
mosquitos harbor the virus for the remainder of their lifetime. 
There are four phylogenetically distinct dengue serotypes—DENV-1, DENV-2, DENV-3, 
and DENV-4. Humans can be infected by all 4 serotypes during their lifetime. Infection with one of 
the four serotypes provides lifelong immunity against the infecting serotype and short-lived 
protection against the other three (8). However, a secondary infection with another serotype may 
result in more severe clinical presentations such as Dengue Hemorrhagic Fever or Dengue Shock 
Syndrome (6). This phenomenon is known as Antibody Dependent Enhancement (ADE). ADE 
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occurs when cross-reactive, non-neutralizing antibodies from a previous infection bind to the novel 
infecting serotype (8). This interaction boosts uptake of the virus by macrophages, resulting in the 
activation of the complement system and an augmented cytokine cascade (7). These immune 
responses result in hemorrhagic manifestations including plasma leakage and low platelet count (7).  
2.2 Dengue Virus Susceptibility 
The severity of dengue in humans is influenced by a range of factors, including the infecting 
serotype, genetic predisposition, pre-existing conditions, age, and nutritional status (9, 10). Figure 
X highlights environmental, viral, vector and human genetic determinants known to influence 
outcome.  
 
 
 
 
 
 
 
 
 
Figure 1. Risk Factors 
 
Understanding human genetic susceptibility is key to understanding and predicting dengue 
pathogenesis. Moreover, this information can potentially aid in the development of anti-dengue 
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vaccines and therapies. Several human genetic polymorphisms, which will be discussed in later 
sections, have been associated with severe hemorrhagic manifestations.  
The relationship between mosquitos and dengue virus is complex. The terms vector 
competence and vectorial capacity can be used to explain mosquito activity. Vector competence 
refers to the vector’s ability to efficiently transmit a pathogen. Vectorial capacity refers to the 
potential number of bites on one host on a single day (11). Interactions between internal, external 
and viral factors such as the microbiota of the mosquito, regional climate, and viral genetics impact 
vector competence (12). The mosquito’s vectorial capacity is ultimately influenced by vector density 
and the frequency of host interaction, in addition to feeding behavior and longevity, which are 
dependent upon its response to the virus (12).  
Some dengue serotypes are suspected to be more virulent than others when comparing 
primary and secondary infections. Research from Fried et al. suggests that in the case of primary 
infections, DENV-1 and DENV-3 are more pathogenic serotypes (13). Furthermore, their research 
also suggests that DENV-2 and DENV-3 are twice as likely to result in DHF in secondary infections 
when compared to DENV-4 (13).  
2.3 Clinical Classification 
The evolving perception of dengue has shaped the clinical classification of the disease over 
the years. Initially, dengue was not considered to be a life-threatening illness. However, outbreaks 
of dengue hemorrhagic fever in Southeast Asian children in the late 1960s prompted the public to 
reconsider (14). Information obtained from these cases became the foundation of the World Health 
Organization’s (WHO) guidelines for the clinical classification of dengue, published in 1975 and 
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updated in 1997 (14). Before 2009, dengue infection was classified into two categories: dengue fever 
and dengue hemorrhagic fever, as seen in figure 2 (14).  
Dengue fever patients presented with fever and at least two of the following symptoms: 
headache, pain behind the eye, myalgia, joint pain, rash, hemorrhagic manifestations and low white 
blood cell count (14). Additionally, serological or epidemiological (same location and timepoint as 
confirmed cases) confirmation was also required (14). Dengue hemorrhagic fever patients presented 
with all four of the following symptoms: fever, hemorrhagic manifestations, low platelet count, and 
plasma leakage. While the case definition of DHF may seem specific, many expressed difficulties 
diagnosing dengue in low-resource or primary care settings (14). Additional arguments include its 
exclusivity of patients experiencing more severe disease and its inapplicability to other regions with 
different epidemiological trends of dengue disease (14). 
 
 
Figure 2. 1997 World Health Organization Classification of Dengue 
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In response to these concerns, WHO reclassified the categories of clinical dengue in 2009, 
as seen in Figure 3. Dengue is currently recognized as dengue, with or without warning signs, and 
severe dengue. Dengue is characterized by a fever with at least two of the following: vomiting, 
nausea, rash, myalgia, a positive tourniquet exam and any warning signs. Similar to the 1997 
classification, serological and epidemiological evidence is required as well.  Warning signs include 
abdominal pain and/or tenderness, persistent vomiting, hepatomegaly, mucosal bleeding, tiredness, 
and fluid accumulation. Patients exhibiting these signs should be closely monitored to prevent 
disease progression. Severe dengue is characterized by any of the following: severe plasma leaking, 
severe bleeding or severe organ impairment of the liver, heart or central nervous system (14). About 
5% of all dengue fever cases will progress to the severe dengue stage (15). While the sensitivity of 
the current system is considered to be superior to the former, issues do exist (16). Determination of 
disease severity may differ by clinician because the current system fails to define the criteria for 
severe dengue (15). Moreover, presence of one of the three clinical components of severe dengue 
does not always indicate severe disease but could be the result of an unrelated diseases or conditions 
(14). Considering its over-inclusivity and use of nonspecific warning signs, it is clear that 
classification requires some modification in order to be effective worldwide.  
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Figure 3. 2009 World Health Organization Classification of Dengue 
2.4 Clinical Presentation 
Clinical presentation of dengue ranges from non-severe to severe manifestations. Due to lack 
of a vaccine or a specific antiviral treatment, timely intervention and adequate understanding of the 
natural history of disease is key to recovery.  
Dengue disease characterized by three distinct phases—febrile, critical, and recovery (Figure 
4). Only patients with severe dengue will experience all three phases (17). Patients in the febrile 
stage develop a high-grade fever following incubation. This phase generally lasts for 2-7 days along 
with common acute febrile illness symptoms such as myalgia, headache, skin erythema, and facial 
flushing (18). The similarities between the symptoms of dengue and other acute febrile illnesses 
make it difficult to accurately diagnose infections in this stage. Since elevated viremia is a critical 
indicator of disease in this phase, serological testing should be performed if dengue is suspected.  
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Warning signs will surface in the late stages of the febrile phase. In the absence of medical 
intervention, the patient will progress to the critical phase. This phase generally lasts for 24-48 hours 
and begins at the time of defervescence (18). It is marked by an increase in hematocrit and capillary 
permeability, along with a decrease in platelet count (18). Most patients who experience this phase 
will recover however those with significant plasma leakage will develop severe dengue (15). During 
the recovery phase, patients begin to reabsorb extravascular fluids that were lost during the critical 
phase and overall health improves (15). Patients may experience fatigue and depression during the 
recovery phase (19).   
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Course of Dengue Illness 
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2.5 Global Burden of Dengue 
Researchers believe that dengue has existed for centuries. Despite the multiple dengue-like 
outbreaks in 1635, 1669, and 1780, a Chinese encyclopedia dated as early as A.D. 265 describes 
symptoms similar to dengue (4, 20). The Chinese referred to the disease as “water poison” and 
associated it with flying insects and water. However, the virus now known as DENV-1 was not 
isolated until 1943 by Ren Kimura and Susuma Hotta during an outbreak in Nagasaki, Japan. (21). 
A year later, Albert Sabin isolated DENV-2 (20). In 1956, William Hammon, the first chair of the 
Department of Infectious Diseases and Microbiology at the University of Pittsburgh Graduate 
School of Public Health isolated DENV-3 and DENV-4 (20). Before 1970, severe dengue epidemics 
were only recorded in 9 countries (5). Since then, the geographical distribution of dengue has 
expanded, and the virus is now present in every WHO region (5, 1). According to the WHO, it is 
now endemic in over 100 countries (5). While Asia carries the largest burden of disease, the South-
East Asia, America and Western Pacific regions are also greatly affected (5).  
Approximately half of the global population is at risk of contracting dengue. The WHO states 
that in the past two decades, the number of reported cases has increased exponentially (5). In 2013, 
researchers in a study by Bhatt et al predicted 390 million dengue infections occur every year and 
approximately 24% of these cases are symptomatic (6). Increases in global incidence and 
hyperendemicity in certain regions can be contributed a number of factors, including inefficient or 
lack of vector control, poor living conditions, international travel, and geographic expansion (7, 1). 
Dengue is generally a non-fatal, self-limiting disease. According to the CDC, approximately 
25% of those infected with the virus will actually develop an illness and about 5% of those cases 
will progress to severe dengue (3). The cost of treatment for these severe cases is often unaffordable 
for individuals or families in low-income countries. It is important to note that mild infections can 
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also negatively impact an individual’s economic stability. Mild symptoms can limit an individual’s 
ability to participate in daily activities, which then affects their ability to pay for necessary 
medications. A 2013 study estimated that the annual global burden of dengue in that year was 8.9 
billion USD, though the true burden was most likely more expensive (23). Specifically, they 
estimated that the short-term costs per case ranged from 31-333 USD (23). This includes direct 
healthcare costs and indirect costs, money lost due to illness. Long-term costs for fatal cases ranged 
from 75,820-80,414 USD (23). As previously stated, it is difficult to estimate the true burden of 
disease due to the misdiagnosis and underreporting of dengue infections. Dengue treatment also 
places a strain on healthcare systems. Without adequate screening criteria for emergency settings in 
hyperendemic regions, overcrowding is likely to occur. 
2.6 History of Dengue in Brazil 
The first Brazilian dengue epidemic was reported in 1845, in Rio de Janeiro (3). Additional 
epidemics were reported from 1853-1851 and 1916-1923. The Pan American Health Organization’s 
urban fever mosquito eradication program, which eliminated the presence of A. aegypti, was 
instrumental in the decline of dengue in Brazil until 1976 (3).  DENV-1 and DENV-4 were the first 
serotypes found in Brazil, as they were discovered to be responsible for the 1981 outbreak (3). 
DENV-2 was later introduced in 1990 after an outbreak in Rio de Janeiro. DENV-3, the cause of the 
2000 outbreak, was the last to appear in Brazil (3). In 2002, with 288,245 reported cases and 91 
deaths, DENV-3 was responsible for one of the largest outbreaks in the country (3). From 1981 and 
2006, there were 4,343,049 reported cases with 5,817 cases of severe dengue and 338 deaths (3). 
Figure 4 highlights the activity of all four serotypes in Brazil from 1845 to 2010. As of today, all 
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four serotypes are endemic in Brazil and continue to threaten the health and well-being of its citizens. 
In 2016, approximately 1.5 million of the total global dengue cases occurred in Brazil, a threefold 
increase from 2014 (3).  Brazil’s climate has sustained the mosquito population and continues to 
provide favorable conditions that allow replication of the species. 
 
Table 1. Dengue Serotype Activity in Brazil from 1845-2010 
 
 
 
 
 
 
 
 
 
2.7 Management and Prevention 
Efforts to reduce the global morbidity and mortality of dengue include but are not limited to 
the following: providing preventative resources and education to affected communities, improving 
vector control strategies, strengthening healthcare systems, training healthcare workers at all levels, 
and providing adequate treatment to severe cases (24). In 2012, the WHO implemented the Global 
Strategy for Dengue Prevention and Control. This eight-year plan was created to mitigate the effects 
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of dengue and reduce the overall global burden of disease (24). Specifically, this plan aimed to 
estimate the exact burden of dengue fever by 2015 (24). It also aimed to reduce global dengue 
morbidity and mortality by at least 25% and 50%, respectively, by 2020 (24). Unfortunately, global 
incidence rates of dengue remain high, despite the WHO’s efforts. In 2019, the Region of the 
Americas recorded the highest number of reported cases to date (25). Barriers of change include 
urbanization, climate changes, and international travel and trade (26). 
Other notable interventions include The PAHO Integrated Management Strategy for Dengue 
Prevention and the World Mosquito Program. PAHO aims to see a 30% reduction in the case fatality 
rate of dengue in the Region of the Americas by 2020. PAHO plans to achieve this through the 
following objectives: enhancing the detection and management of dengue, improving surveillance 
systems and genetically monitoring the virus (27). The World Mosquito Program has implemented 
a unique method to combat the spread of diseases via A. aegypti mosquitoes. Researchers have 
discovered that mosquitoes carrying Wolbachia are less likely to transmit viruses to humans (31). 
This program breeds Wolbachia-infected mosquitoes and releases them into communities which are 
highly impacted by mosquito-borne diseases (31). However, like many interventions, there are some 
limitations. Most notably, the A. aegypti is not the sole vector for all mosquito-borne diseases. 
The current dengue vaccine, Dengvaxia, is licensed in 20 countries and is only administered 
to individuals between the ages of 9 to 45 (47). A major limitation of this vaccine stems from the 
fact that it can only be administered to dengue-seropositive individuals, those who have previously 
been exposed to the virus. Global controversy behind Dengvaxia arose in 2017 after Filipino 
children, who were suspected to have had a previous exposure to dengue, either experienced negative 
health outcomes or died after receiving the vaccine (46). Issues such as these signify the importance 
of continued vaccine research. 
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3.0 Methods 
3.1 Research Question 
Is there an association between the selected single nucleotide polymorphisms (SNPs) and 
host susceptibility to severe dengue in these samples? 
3.2 Sample Selection 
The DNA samples used in this project belong to a cohort of dengue patients in Recife, Brazil 
(34). This study was conducted at the Aggeu Magalhães Research Center by researchers in the 
Department of Virology (34). Patients were recruited from 2004-2006 at three different hospitals in 
Recife— the Hospital Esperança, Hospital Santa Joana and Instituto Materno Infantil. Each patient 
was admitted to one of the three hospitals with suspected dengue fever. Patients under the age of 
five were not eligible to participate (34). Blood samples were collected from all patients to perform 
necessary confirmatory laboratory testing. All positive cases were confirmed by testing to be caused 
by DENV-3. All suspected cases were not dengue positive. Patients found to be dengue-free were 
used as controls for this thesis project. Additionally, patients from a yellow fever vaccine cohort, 
which also took place in Recife, Brazil, were included in the control group as well. Eligible patients 
were required to be at least 10 years of age with no prior history of dengue infection (35). Serological 
testing was performed on all patients prior to immunization. 
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Dengue-positive patients were classified into three groups—classic dengue, complicated 
dengue and dengue hemorrhagic fever. Prior to the 2009 revision, researchers and physicians found 
that some cases did meet the all criteria for the WHO classifications of dengue fever, specifically for 
dengue hemorrhagic fever. In this case, the complicated dengue category was created for patients 
who presented with dengue fever symptoms, hemorrhagic manifestations and low platelet count, but 
did not meet the laboratory criteria required by the WHO (34).  
Patients in the dengue cohort were also classified by infection type—primary or secondary. 
Primary cases lacked the presence of anti-dengue IgG antibodies following initial infection but were 
positive for anti-dengue IgM and IgG in convalescent serum samples (34). Secondary cases were 
characterized by the presence of anti-dengue IgG antibodies in acute serum samples and the absence 
of anti-dengue IgM antibodies (34). However, convalescent serum samples of secondary cases 
showed a presence of anti-dengue IgM antibodies.  
3.3 Single Nucleotide Polymorphisms of Interest 
As previously stated, human genetic variants can influence infectious disease susceptibility. 
Associations between genetic polymorphisms and susceptibility have been identified for infectious 
diseases such as hepatitis B and C, malaria, tuberculosis and HIV-1 (28). This study investigates the 
association between 18 single nucleotide polymorphisms (SNPs) and severe dengue. The 
polymorphisms in question, along with the corresponding gene, can be found in Table 1. The first 
11 SNPs were identified in a study which predicted dengue fever severity using human genome data 
and machine learning (29). PLCE1 rs3740360 was shown to be significantly associated with Dengue 
Shock Syndrome in a Vietnamese pediatric study (30). MRC1 rs606231248, formerly rs34039386, 
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and MRC1 rs2296414 were found to be associated with severe dengue by former students Erin 
Cathcart and Hannah Polglase (39,40). OASL rs3212545 and RNASEL rs486907 have been shown 
to be associated with increased susceptibility to severe West Nile virus disease, a close relative of 
dengue virus (33). Due to this association, the aforementioned SNPs may be of interest in this 
analysis. MICB rs3132468 was found to be a risk factor for dengue shock syndrome in Thai children 
(32). Lastly, MX1 rs7277299 is associated with a gene that participated in the cellular antiviral 
response so variants of this gene may increase dengue susceptibility as well (45).  
 
Table 2. Selected SNPs and Corresponding Genes 
SNP Gene SNP Gene 
rs17256081 Toll-like receptor 8 (TLR8) rs4251580 Interleukin-1 receptor-associated 
kinase 4 (IRAK4) 
rs2069718 Interferon gamma (IFNG) rs17199006  C-Type Lectin Domain Family 4 
Member C (CLEC4C) 
rs2069727 Interferon gamma (IFNG) rs3740360 Phospholipase C Epsilon 1 (PLCE1) 
rs2070729 Interferon regulatory factor 1 
(IRF1) 
rs606231248 Mannose Receptor C-Type 1 
(MRC1) 
rs2072137 Oligoadenylate synthase 2 
(OAS2) 
rs2296414 Mannose Receptor C-Type 1 
(MRC1) 
rs2072138 Oligoadenylate synthase 2 
(OAS2) 
rs486907 Ribonuclease L (RNASEL) 
rs2240188 Oligoadenylate synthase 3 
(OAS3) 
rs3213545 Oligoadenylate Synthetase Like 
(OASL) 
rs3737399 MX dynamin like GTPase 1 
(MX1) 
rs7277299 MX dynamin like GTPase 1 (MX1) 
rs3911403 Ventricular zone expressed ph 
domain containing 1 
(VEPH1) 
rs3132468 
 
MHC class I polypeptide-related 
sequence B (MICB) 
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3.4 Genotyping 
Due to the large sample size, samples were sent to the University of Pittsburgh’s Genomics 
Research Core Laboratory for SNP genotyping. Prior to plating and transport, the concentrations of 
all samples were tested using a Nanodrop 1000 Spectrometer. Concentrations ranged from 10-100 
ng/L, per the laboratory technician’s request. Samples with concentrations over 100 L were 
diluted within acceptable range using Tris-EDTA buffer. Samples were then plated on 96 well plates 
and stored at 4 degrees Centigrade until transport. Samples were then genotyped at the Genomics 
Research Core by polymerase chain reaction, single-base primer extension, and mass spectrometry 
using the iPlex MassARRAY system (Agena Bioscience). 
3.5 Data Analysis 
The demographic data of the total sample population was analyzed using Microsoft Excel. 
Samples were sorted by age, sex and dengue disease status — dengue fever (DF), complicated 
dengue (CD), and dengue hemorrhagic fever (DHF). Principal component analysis (PCA) was 
performed on these samples, using R statistical software, to group samples into clusters by SNPs 
and disease status (severe vs. mild disease). PCA is an unbiased approach that was used to cluster 
samples based on their overall similarities in genotype at each of the 18 SNPs for which we have 
data. If these SNPs collectively impact dengue disease outcome, then samples with the same disease 
classification should cluster together in the PCA. HWE and chi-square testing was performed using 
Microsoft Excel to check the reliability of the genotypes obtained. Using genotypic data, odds ratios 
(ORs) were performed for all SNPs to determine the odds of developing severe disease. Odds ratios 
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were calculated using Microsoft Excel. P-value and 95% confidence interval calculations were 
provided for each OR as well. 
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4.0 Results 
4.1 Demographics of Total Population 
Demographic data was analyzed using Microsoft Excel. Results can be found in Table 2. Of 
the 450 samples, 225 were confirmed dengue cases. Females represented 58.4% of the population 
and males represented 41.6%. When combining both sexes, patients within the 30-39 age group had 
the highest percentage of disease, followed by the 0-19 age group. Overall, younger populations 
were more affected by dengue in this sample.  
 
Table 3. Distribution of Age and Sex in Total Population 
 Age   
Sex 0-19 20-29 30-39 40-49 50-59 60-69 70-79 TOTAL % 
Female 28 29 34 23 13 4 1 132 58.7% 
Male 26 12 23 20 9 2 1 93 41.3% 
TOTAL 54 41 57 43 22 6 2 225  
% 24.0% 18.2% 25.3% 19.1% 9.8% 2.7% 0.9% 100.0%  
 
Overall, there were 132 confirmed dengue cases in the female population, with the highest 
number of cases being seen in the complicated dengue (CD) group. The lowest number of cases 
were seen in the dengue hemorrhagic fever (DHF) group, which is expected due to the rarity of the 
condition. This group represented 47.73% of the total female population. Results can be seen in 
Table 3. Again, younger age groups were more affected in this population as well. Table 4 displays 
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the distribution of dengue cases by age group in the male population. The older populations for both 
sexes are not well represented in this sample. Similar to the female population, the complicated 
dengue group carries the largest burden of disease among males.  
 
Table 4. Distribution of Disease by Age in Female Population 
 Diagnosis  
Age DF CD DHF Total 
0-19 16 12 0 28 
20-29 11 7 11 29 
30-39 8 23 3 34 
40-49 5 13 5 23 
50-59 7 6 0 13 
60-69 1 2 1 4 
70-79 0 0 1 1 
Total 48 63 21 132 
% 33.36% 47.73% 15.91% 100.00% 
 
Table 5. Distribution of Disease by Age in Male Population 
 Diagnosis  
Age DF CD DHF Total 
0-19 13 10 3 26 
20-29 5 7 0 12 
30-39 1 20 2 23 
40-49 7 12 1 20 
50-59 4 5 0 9 
60-69 1 0 1 2 
70-79 0 1 0 1 
Total 31 55 7 93 
% 33.33% 59.14% 7.53% 100.00% 
 
Infection type data was provided for 189 of the 225 dengue cases. Results can be found in 
Figure 5. The highest number of primary and secondary infections were observed in the CD group, 
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51 and 55 respectively. Interestingly, there were more primary infections in the DHF group and more 
secondary infections in the dengue fever group. In total, there were 94 primary infections and 95 
secondary infections.  
 
 
 
 
 
 
 
 
 
Figure 5. Distribution of Primary and Secondary Infections 
4.2 Principal Component Analysis 
Principal component analysis was used to group samples into two clusters by disease status, 
mild vs. severe dengue. However, the results were not very informative. Theoretically, if there were 
differences in in the distribution of genotypes for each disease group, two distinct clusters would be 
present in the plot. All 18 SNPs were used to create Figure 6. Figure 7 is based on the 11 SNPs that 
were predicted to be associated with severe dengue using human genome data and machine learning 
by Davi et al. Possible explanations for the lack of clusters will be discussed in later sections.   
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Figure 6. Principal Component Analysis of 18 SNPS 
 
 
Figure 7. Principal Component Analysis of 11 Predicted SNPs 
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4.3 Hardy Weinberg Equilibrium 
HWE testing was performed to compare the observed and expected allele frequencies. HWE 
is based upon the following principle: genotype frequencies among a population will remain constant 
in the absence of disrupting factors. HWE was calculated for the whole sample, cases, controls and 
by disease status. To evaluate the significance of the differences between the observed and expected 
genotype frequencies, chi-squared testing was performed. All observed genotypes were in HWE 
across all disease categories, cases and controls except for the following: rs606231248, rs3737399, 
rs17256081, rs2070729, rs3911403, and rs486907. Possible reasons for these discrepancies will be 
highlighted in the discussion section. 
4.4 Genotype and Allele Frequencies 
This section includes data for each SNP on the observed genotypes and alleles among this 
Brazilian population. Genotype and allele frequency data per SNP can be found in the appendix 
section in Table 1. The CD group was the most represented disease group and the DHF group was 
the least represented for all SNPs. 
4.4.1  MRC1 rs2296414 
The frequency of the CC genotype for the entire sample, including non-dengue cases, was 
71.91%. The frequencies of the CT and TT genotypes were 25.91% and 2.18%, respectively. In 
terms of alleles, the T allele was more common, with a frequency of 84.87% in the total sample.  
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4.4.2  CLEC4C rs17199006 
The frequencies of AA, GA and GG in the whole sample were 74.01%, 24.34%, and 1.64%, 
respectively. The frequency of the A allele was 86.18% and the frequency of the T allele was 
13.82%.  
4.4.3  TLR8 rs17256081 
Results for this SNP show that the TT was the most frequent genotype in the entire 
population, with a frequency of 51.56%. The frequency of CC and CT was 27.60% and 20.83%, 
respectively. The T allele was the more represented allele among this population. 
4.4.4  IFNG rs2069718 
The most frequent genotype among the entire sample was AG, with a proportion of 54.04%. 
The frequencies of AA and GG in the total sample were 17.42% and 28.53%, respectively. The G 
allele was more common among this population.  
4.4.5  IFNG rs2069727 
The frequencies of the CC, CT and TT genotypes in the entire population were 14.43%, 
48.17%, and 37.41%, respectively. The distribution of the T allele was higher than the C allele. 
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4.4.6  IRF1 rs2070729 
The frequencies of the AA, CA and CC genotypes in the entire population were 23.02%, 
54.42%, and 22.56%, respectively. The C and A alleles were evenly distributed across all samples. 
4.4.7  OAS2 rs2072137 
The frequencies of the CC, TC, and TT genotypes in the entire population were 15.65%, 
43.28%, 41.08%, respectively. The frequency of the T allele was 62.71% and the frequency of the 
C allele was 37.29%.  
4.4.8  OAS2 rs2240188 
The distribution of the CC and CT genotypes among this sample were very similar. The 
frequency of the CC genotype was 44.03% and the frequency of the CT genotype was 44.50%. The 
TT genotype is least represented in this sample, with a frequency of 11.48%. This finding explains 
the high percentage of C alleles in the population. 
4.4.9  MICB rs3132468 
The distribution of the T allele is significantly higher than that of the C allele in this 
population.  The CC genotype was present in a small percentage of the confirmed and non-dengue 
cases. The frequency of the TC and TT genotypes was 31.67% and 64.52%.    
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4.4.10  OASL rs3213545 
Similar to the last, the distribution of the G allele is significantly higher than that of the A 
allele in this population.  The AA genotype was present in a small percentage of the confirmed and 
non-dengue cases. The frequency of the GA and GG genotypes was 38.15% and 56.64%.    
4.4.11  MX1 rs3737399 
The distribution of the CC genotype among the entire population was significantly higher 
than that of the CT and TT genotypes. The frequency of the CC genotype was 77.12%. The CT 
genotype was not detected in the CD or DHF groups and the frequency of the genotype in the entire 
population was 1.03%. The frequency of the C allele was 77.63%.  
4.4.12  PLCE1 rs3740360 
The CC genotype was not detected in this sample. The distribution of the AA genotype, 
81.19%, was significantly higher than that of the CA genotype, 18.81%. As expected, the frequency 
of the A allele was also higher than the C allele.  
4.4.13  VEPH1 rs3911403 
The frequencies of the AA, TA and TT genotypes were 3.03%, 23.48%, and 73.48%. The 
frequency of the T allele, 85.23%, was significantly higher than the A allele, 14.77%. 
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4.4.14  IRAK4 rs4251580 
The there is a greater presence of the C allele in this sample. The frequency of the CC 
genotype was 76.26%, followed by 22.35% for the CT genotype. The lowest frequency was observed 
for the TT genotype at 1.40%. As expected, the frequency of the C allele, 87.43%, was significantly 
higher than the T allele, 12.57%.  
4.4.15  RNASEL rs486907 
The highest proportion of samples was seen in the CC genotype, followed by CT. The 
frequencies were 50.63% and 39.35%, respectively. The frequency of TT was 10.02%.  
4.4.16  MRC1 rs606231248 
The frequencies of the AA, AG and GG genotypes were 8.02%, 26.07%%, and 65.91%. The 
frequency of the G allele, 78.95%, was significantly higher than the A allele, 21.05%. 
4.4.17  MX1 rs7277299 
The proportion of the A allele is very low in this population. The AA genotype was not 
present at all and the CA genotype was only present in 26 samples. The frequency of the CC 
genotype was 93.55% and the frequency of the C allele was 96.77%. 
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4.4.18  OAS2 rs2072138 
The genotyping results for this SNP revealed the presence of three alleles, A, C and G. The 
highest percentage of samples were seen in the CC group at 45.89%, followed by the GC group at 
39.27%. The frequencies of the AA, GG and CA genotypes were 6.85%, 6.39% and 1.60%. The C 
allele had the highest frequency among the population with 71.03%, followed by the G allele 
(24.45%) and the A allele (4.52%).  
4.5 Odds Ratios 
Odds ratios were calculated for each of the 18 SNPs in order to determine if certain genotypes 
were associated with severe dengue. Additionally, these calculations will uncover which alleles act 
in dominant and recessive manners. Severe dengue (CD+DHF) and dengue fever (DF) groups were 
used for all odds ratios. Insignificant odds ratio results can be found in the appendix section in Table 
2.  
There were 4 significant results from this analysis (Table 22). The first was found for 
rs2072137. The CC genotype was shown to be significantly associated with severe dengue 
(OR=2.10, P=0.01). The next significant result (OR=1.96, P=0.02) was found for rs2240188, where 
the CC genotype also appears to influence disease severity.  The odds ratios for rs3740360 reveal a 
significant association between the A allele and severe dengue (OR=2.28, P=0.03). The last notable 
result was found in rs7277299 (OR=5.33, P=0.02) where the CC genotype was also significantly 
associated with severe disease.  
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Table 6. Significant Odds Ratios 
rs2072137 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
TT+TC 116 60 
1.55 0.75 – 3.20 0.2401 
CC 20 16 
TT 67 24 
2.10 1.17 – 3.79 0.0133 
TC+CC 69 52 
rs2240188 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
CC+CT 123 64 
1.67 0.75 – 3.71 0.2123 
TT 15 13 
CC 69 26 
1.96 1.10 – 3.50 0.0224 
CT+TT 69 51 
rs3740360 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
AA+CA 129.5 74.5 
1.74 0.03 – 88.52 0.7828 
CC 0.5 0.5 
AA 112 55 
2.28 1.10 – 4.72 0.0272 
CA+CC 17 19 
rs7277299 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
CC+CA 135.5 74.5 
1.82 0.04 – 92.61 0.7655 
AA 0.5 0.5 
CC 132 66 
5.33 1.37 – 20.77 0.0158 
CA+AA 3 8 
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5.0 Discussion 
5.1 Demographics 
Results show that more women were infected with dengue virus than men in this population. 
While this is a small sample size, the results correlate with Cordeiro’s findings on dengue 
distribution across sexes (34) and that of other Latin American countries (34, 37). The male to female 
ratio in Brazil from 2001-2010 was 0.75 to 0.82 (37). Further analysis of health data records in Brazil 
show a higher percentage of confirmed dengue cases in women, suggesting that they may seek care 
more often than men (34). Reasoning behind these differences in Brazil should be studied further.   
As seen in Figure 5, the number of primary and secondary infections in the complicated 
dengue group are similar. In terms of secondary infections, the data is consistent with the literature 
on dengue pathogenesis. Researchers have concluded that secondary infections increase severe 
dengue risk through ADE. However, it is interesting to see such a similar number of primary 
infections in this group. Moreover, there was a larger percentage of primary infections in the dengue 
hemorrhagic group. One explanation for these finding could be the pathogenesis of the infecting 
serotype. As previously stated, certain serotypes elicit a more severe reaction than others. The results 
in the dengue fever group are noteworthy as well. There was a larger percentage of secondary 
infections in this group, which contradicts the ADE phenomenon. While these findings are 
intriguing, it is important to note that infection type data was not provided for all 225 dengue cases.  
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5.2 Principal Component Analysis 
The results of the PCA plot do not reveal any significant correlation between disease groups 
and SNPs. There was no clear difference in the distribution of genotypes across mild and severe 
disease groups. One explanation for this could include the restrictions of the PCA algorithm—it 
requires complete data. In order to create a plot, genotype data must be present for all samples. Any 
sample that did not produce genotype data for a particular SNP was excluded from the algorithm. 
Out of the 225 dengue cases, only 164 were included in the plot (60 dengue fever and 104 severe 
dengue). These exclusions may have affected the clustering of samples. It would be better to test the 
predictions made by Davi et al using a larger sample size with complete genotype data.  
5.3 Hardy Weinberg Equilibrium 
All observed genotypes were in HWE across all disease categories, cases and controls except 
for the following: MRC1 rs606231248, MX1 rs3737399, TLR8 rs17256081, IRF1 rs2070729, 
VEPH1 rs3911403, and RNASEL rs486907. Deviations from HWE could be due to the following: 
mutations, nonrandom mating, small sample size, gene flow or migration, and natural selection. 
Deviations can also be caused by genotyping errors. No genotyping technique is completely accurate 
and there may have been faults with the particular method used in this study. No significant results 
were observed for these 6 SNPs. Deviations from HWE may impact the ability to detect significant 
associations between the disease groups and SNPs. 
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5.4 Genotype/Allele Frequencies 
Observed allele frequencies were compared to global frequencies from the National Library 
of Medicine’s Reference SNP database. Comparison of the two revealed similarities in the observed 
frequencies in this project and those listed in the database. Among the aforementioned HWE 
deviations, IRF1 rs2070729 was the only SNP that did not follow allelic trends in the database. The 
library’s records indicate that the frequency of the C allele should be higher than the A allele, 
however, that is not the case in this project. The frequencies of the C and A alleles were 49.77% and 
50.23%, respectively, indicating an almost even distribution of both alleles. Several reasons could 
explain this difference—genotyping errors, genetic differences between populations, and small 
sample size. Information on the allele and genotype frequencies for all other SNPs can be found 
below.  
5.5 Significant Odds Ratios 
5.5.1  OAS2 rs2072137 and OAS3 rs2240188 
The odds ratio calculations for OAS2 rs2072137 revealed a significant association between 
severe dengue and the TT genotype in this population (OR=2.10, p=0.0133). Calculations for OAS3 
rs2240188 revealed a significant association between the CC genotype and severe dengue (OR=1.96, 
p=0.0224). The OAS gene family, located on chromosome 12, has been shown to encode for 
interferon-inducing proteins, which play a crucial role in the innate immune system’s antiviral 
response via the OAS/RNase L pathway (41). Specifically, 2’-5’ oligoadenylate production occurs 
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after the 2’-5’ oligoadenylate synthetases recognize viral RNA (41). The 2’-5’ oligoadenylates then 
bind to RNase L which cleaves viral and cellular RNA, resulting the inhibition of viral protein 
synthesis and replication (42). Given its antiviral activity, variations of the OAS gene could have 
significant effects on the body’s ability to fight dengue infection.  
5.5.2  PLCE1 rs3740360 
A significant association was seen between the AA genotype and severe dengue (OR=2.28, 
p=0.0272) for PLCE1 rs3740360. Mutations in the PLCE1 gene, located on chromosome 10, are 
associated with nephrotic syndrome, a kidney disorder that causes hypoproteinemia and the presence 
of protein in urine (43). Severe symptoms lead to edema and a decrease in vascular oncotic pressure 
(43). Given that proteinuria and plasma leakage are also characteristics of severe dengue, it is 
possible that the physiological processes of severe dengue and nephrotic syndrome share similarities. 
Additionally, expression of the PLCE1 encodes a phospholipase enzyme that is responsible for the 
production of inositol 1,4,5-triphosphate and diacylglycerol, which regulate several cellular 
processes (44). 
5.5.3  MX1 rs7277299 
For MX1 rs7277299, a significant association was seen between the CC genotype and severe 
dengue (OR=5.33, p=0.0158). The MX1 gene, located on chromosome 4, inhibits viral replication 
by encoding guanosine triphosphate-metabolizing proteins, which are induced by type I and II 
interferons (45).  
  33 
6.0 Public Health Significance 
As climate change continues to alter the normalcy of our lives, it may also affect the spread 
of disease-carrying insects. Specifically, climate change may contribute to the proliferation of the 
mosquito population. As a result of this increase, mosquito-borne diseases may be spread to areas 
where they were previously eradicated or nonexistent. Climate change threatens the health and well-
being of global populations and without a safe dengue vaccine, communities will lack complete 
protective immunity. 
Vaccine development for dengue has been ongoing for at least 90 years (36). However, like 
other vaccines, it is challenging to create effective products without proper understanding of the 
virus and how it interacts with the human immune system.  Genetic association studies are used to 
understand and predict how the human immune system will respond after vaccine exposure. They 
may also aid in the identification of vaccine targets. A better understanding of the genetic 
implications in dengue pathogenesis are necessary in order to develop a tetravalent vaccine that is 
safe for all populations, regardless of prior exposure to dengue. 
Health clinics and emergency departments in dengue-endemic areas are burdened with a high 
number of patients daily. In many of these areas, it is difficult to diagnose dengue cases due to the 
presence of other acute febrile illnesses. However, those exhibiting dengue symptoms must be 
closely monitored to prevent progression to severe dengue, often causing unnecessary, long-term 
hospital admittances. This places a major strain on the staff and increases healthcare spending for 
the hospital and the patient. To mitigate these effects, genetic association studies can be used to 
develop triage tools that can accurately identify patients at an increased risk of developing severe 
dengue.  
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7.0 Conclusion 
With over 50 percent of the global population at risk of infection, dengue carries significant 
global importance. Contributing factors to the spread of dengue include urbanization, inadequate 
vector control, climate change, and increased international travel. A large percentage of cases are 
asymptomatic, making it difficult to estimate the true burden of dengue worldwide. With the 
increasing global burden, it is more important than ever to develop an effective antiviral treatment 
and vaccine against dengue. 
This study found a significant association between severe dengue and the following SNPs: 
OAS2 rs2072137, OAS3 rs2240188, PLEC1 rs3740360, and MX1 rs7277299. The OAS and MX1 
genes have been shown to influence to the immune response against viral infections by restricting 
viral replication (41, 45). The PLCE1 gene is suspected to play a role in the clinical outcome of 
infection and possibly the integrity of the endothelial function (43). However, these findings should 
be evaluated using a larger sample size.  
Several limitations exist in this study. Since all samples were collected in Recife, Brazil, this 
study not representative of the entire Brazilian population. Results cannot be generalized to the entire 
Brazilian or global population since the epidemiology of dengue varies by region and possibly by 
race/ethnicity. This population also lacked diversity in age group. As stated in the demographics 
section, the older population was not represented well. If this study were to be replicated, it should 
be done with a larger and more diverse population. Another limitation of this study is the small 
sample size, which reduces the statistical power and increases the margin of error, thus affecting the 
reliability of the study. This limitation may also lower the reproducibility of the results.  A third 
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limitation is the lack of infection type data for all samples. There was not enough information on the 
samples to examine the relationship between infection type and disease status.  
Researchers have been working to understand the nature of dengue for the past decade. The 
complexity of this virus poses a great barrier to the advancement of prevention measures, treatments, 
and vaccine development.  As the epidemiology of dengue continues to change, further research is 
necessary in order to better understand the nature of the virus. There is still much to be discovered 
about dengue fever, but it is possible that these results can provide greater insight into dengue 
pathogenesis and susceptibility.  
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Appendix Supplemental Tables 
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Table 7. Genotype and Allele Distribution of SNPs 
rs2296414 
Genotypes DF CD DHF ND TOTAL 
CC 51 80 16 150 297 
CT 25 29 7 46 107 
TT 0 4 2 3 9 
No Data 3 5 3 26 37 
Informative: 76 113 25 199 413 
 
Alleles DF CD DHF ND TOTAL 
C 127 189 39 346 701 
T 25 37 11 52 125 
T frequency 16.45% 16.37% 22.00% 13.07% 15.13% 
C frequency 83.55% 83.63% 78.00% 86.93% 84.87% 
rs17199006 
Genotypes DF CD DHF ND TOTAL 
AA 50 58 18 99 225 
GA 12 26 3 33 74 
GG 0 1 0 4 5 
No Data 17 33 7 89 146 
Informative: 62 85 21 136 304 
 
Alleles DF CD DHF ND TOTAL 
A 112 142 39 231 524 
G 12 28 3 41 84 
G frequency 9.68% 16.47% 7.14% 15.07% 13.82% 
A frequency 90.32% 83.53% 92.86% 84.93% 86.18% 
rs17256081 
Genotypes DF CD DHF ND TOTAL 
CC 19 21 8 58 106 
CT 19 25 7 29 80 
TT 34 59 9 96 198 
No Data 7 13 4 42 66 
Informative: 72 105 24 183 384 
 
Alleles DF CD DHF ND TOTAL 
C 57 67 23 145 292 
T 87 143 25 221 476 
T frequency 60.42% 68.10% 52.08% 60.38% 61.98% 
C frequency 39.58% 31.90% 47.92% 39.62% 38.02% 
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rs2069718 
Genotypes DF CD DHF ND TOTAL 
AA 12 22 3 32 69 
AG 38 55 16 105 214 
GG 25 29 5 54 113 
No Data 4 12 4 34 54 
Informative: 75 106 24 191 396 
 
Alleles DF CD DHF ND TOTAL 
A 62 99 22 169 352 
G 88 113 26 213 440 
G frequency 58.67% 53.30% 54.17% 55.76% 55.56% 
A frequency 41.33% 46.70% 45.83% 44.24% 44.44% 
rs2069727 
Genotypes DF CD DHF ND TOTAL 
CC 13 14 4 28 59 
CT 39 51 15 92 197 
TT 24 46 6 77 153 
No Data 3 7 3 28 41 
Informative: 76 111 25 197 409 
 
Alleles DF CD DHF ND TOTAL 
C 65 79 23 148 315 
T 87 143 27 246 503 
T frequency 57.24% 64.41% 54.00% 62.44% 61.49% 
C frequency 42.76% 35.59% 46.00% 37.56% 38.51% 
rs2070729 
Genotypes DF CD DHF ND TOTAL 
AA 20 20 7 52 99 
CA 37 70 13 114 234 
CC 19 24 6 48 97 
No Data 3 4 2 11 20 
Informative: 76 114 26 214 430 
 
Alleles DF CD DHF ND TOTAL 
A 77 110 27 218 432 
C 75 118 25 210 428 
C frequency 49.34% 51.75% 48.08% 49.07% 49.77% 
A frequency 50.66% 48.25% 51.92% 50.93% 50.23% 
Table 7 Continued 
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rs2072137 
Genotypes DF CD DHF ND TOTAL 
CC 16 17 3 28 64 
TC 36 39 10 92 177 
TT 24 55 12 77 168 
No Data 3 7 3 28 41 
Informative: 76 111 25 197 409 
 
Alleles DF CD DHF ND TOTAL 
C 68 73 16 148 305 
T 84 149 34 246 513 
T frequency 55.26% 67.12% 68.00% 62.44% 62.71% 
C frequency 44.74% 32.88% 32.00% 37.56% 37.29% 
rs2240188 
 DF CD DHF ND TOTAL 
CC 26 55 14 93 188 
CT 38 43 11 98 190 
TT 13 14 1 21 49 
No Data 2 6 2 13 23 
Informative: 77 112 26 212 427 
 
Alleles DF CD DHF ND TOTAL 
C 90 153 39 284 566 
T 64 71 13 140 288 
T frequency 41.56% 31.70% 25.00% 33.02% 33.72% 
C frequency 58.44% 68.30% 75.00% 66.98% 66.28% 
rs3132468 
Genotypes DF CD DHF ND TOTAL 
CC 3 4 1 8 16 
TC 30 39 8 56 133 
TT 43 70 17 141 271 
No Data 3 5 2 20 30 
Informative: 76 113 26 205 420 
 
Alleles DF CD DHF ND TOTAL 
C 36 47 10 72 165 
T 116 179 42 338 675 
T frequency 76.32% 79.20% 80.77% 82.44% 80.36% 
C frequency 23.68% 20.80% 19.23% 17.56% 19.64% 
Table 7 Continued 
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rs3213545 
Genotypes DF CD DHF ND TOTAL 
AA 3 6 1 12 22 
GA 27 39 14 81 161 
GG 46 68 10 115 239 
No Data 3 5 3 17 28 
Informative: 76 113 25 208 422 
 
Alleles DF CD DHF ND TOTAL 
A 33 51 16 105 205 
G 119 175 34 311 639 
G frequency 78.29% 77.43% 68.00% 74.76% 75.71% 
A frequency 21.71% 22.57% 32.00% 25.24% 24.29% 
rs3737399 
Genotypes DF CD DHF ND TOTAL 
CC 59 82 18 141 300 
CT 1 0 0 3 4 
TT 15 26 5 39 85 
No Data 4 10 5 42 61 
Informative: 75 108 23 183 389 
 
Alleles DF CD DHF ND TOTAL 
C 119 164 36 285 604 
T 31 52 10 81 174 
T frequency 20.67% 24.07% 21.74% 22.13% 22.37% 
C frequency 79.33% 75.93% 78.26% 77.87% 77.63% 
rs3740360 
Genotypes DF CD DHF ND TOTAL 
AA 55 92 20 148 315 
CA 19 13 4 37 73 
CC 0 0 0 0 0 
No Data 5 13 4 40 62 
Informative: 74 105 24 185 388 
 
Alleles DF CD DHF ND TOTAL 
A 129 197 44 333 703 
C 19 13 4 37 73 
C frequency 12.84% 6.19% 8.33% 10.00% 9.41% 
A frequency 87.16% 93.81% 91.67% 90.00% 90.59% 
Table 7 Continued 
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rs3911403 
Genotypes DF CD DHF ND TOTAL 
AA 1 5 0 6 12 
TA 19 18 4 52 93 
TT 55 84 20 132 291 
No Data 4 11 4 35 54 
Informative: 75 107 24 190 396 
 
Alleles DF CD DHF ND TOTAL 
A 21 28 4 64 117 
T 129 186 44 316 675 
T frequency 86.00% 86.92% 91.67% 83.16% 85.23% 
A frequency 14.00% 13.08% 8.33% 16.84% 14.77% 
rs4251580 
Genotypes DF CD DHF ND TOTAL 
CC 51 84 17 121 273 
CT 20 15 6 39 80 
TT 0 2 0 3 5 
No Data 8 17 5 62 92 
Informative: 71 101 23 163 358 
 
Alleles DF CD DHF ND TOTAL 
C 122 183 40 281 626 
T 20 19 6 45 90 
T frequency 14.08% 9.41% 13.04% 13.80% 12.57% 
C frequency 85.92% 90.59% 86.96% 86.20% 87.43% 
rs486907 
Genotypes DF CD DHF ND TOTAL 
CC 33 48 10 111 202 
CT 34 51 12 60 157 
TT 7 10 2 21 40 
No Data 5 9 4 33 51 
Informative: 74 109 24 192 399 
 
Alleles DF CD DHF ND TOTAL 
C 100 147 32 282 561 
T 48 71 16 102 237 
T frequency 32.43% 32.57% 33.33% 26.56% 29.70% 
C frequency 67.57% 67.43% 66.67% 73.44% 70.30% 
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rs606231248 
Genotypes DF CD DHF ND TOTAL 
AA 5 12 2 13 32 
AG 16 28 6 54 104 
GG 51 66 16 130 263 
No Data 7 12 4 28 51 
Informative: 72 106 24 197 399 
 
Alleles DF CD DHF ND TOTAL 
A 26 52 10 80 168 
G 118 160 38 314 630 
G frequency 81.94% 75.47% 79.17% 79.70% 78.95% 
A frequency 18.06% 24.53% 20.83% 20.30% 21.05% 
rs7277299 
Genotypes DF CD DHF ND TOTAL 
AA 0 0 0 0 0 
CA 8 2 1 15 26 
CC 66 108 24 179 377 
No Data 5 8 3 31 47 
Informative: 74 110 25 194 403 
 
Alleles DF CD DHF ND TOTAL 
A 8 2 1 15 26 
C 140 218 49 373 780 
C frequency 94.59% 99.09% 98.00% 96.13% 96.77% 
A frequency 5.41% 0.91% 2.00% 3.87% 3.23% 
rs2072138 
Genotypes DF CD DHF ND TOTAL 
AA 3 5 2 20 30 
CC 32 54 13 102 201 
GG 6 10 0 12 28 
CA 0 3 1 3 7 
GC 38 43 11 80 172 
No Data 0 3 1 8 12 
Informative: 41 69 15 134 438 
 
Alleles DF CD DHF ND TOTAL 
A 3 8 3 23 37 
C 102 154 38 287 581 
G 44 53 11 92 200 
A frequency 2.01% 3.72% 5.77% 5.72% 4.52% 
C frequency 68.46% 71.63% 73.08% 71.39% 71.03% 
G frequency 29.53% 24.65% 21.15% 22.89% 24.45% 
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Table 8. Insignificant Odds Ratios 
rs17199006 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
GG+GA 30 12 
1.64 0.77 - 3.51 0.1986 
AA 76 50 
GG 1.5 0.5 
1.78 0.07 - 44.30 0.7260 
GA+AA 105.5 62.5 
rs17256081 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
CC+CT 61 38 
0.80 0.45 – 1.43 0.4556 
TT 68 34 
CC 29 13 
1.18 0.57 – 2.46 0.6548 
CT+TT 100 53 
rs2069718 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
AA+AG 96 50 
1.41 0.76 – 2.62 0.2751 
GG 34 25 
AA 25 12 
1.25 0.59 – 2.66 0.5629 
AG+GG 105 63 
rs2069727 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
TT+CT 118 63 
1.35 0.62 – 2.94 0.2751 
CC 18 13 
TT 52 24 
1.34 0.74 – 2.43 0.3331 
CT+CC 84 52 
rs2070729 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
AA+CA 110 57 
1.22 0.63 – 2.36 0.5498 
CC 30 19 
AA 27 20 
0.69 0.36 – 1.34 0.2787 
CA+CC 109 56 
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rs2296414 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
 
 
Odds Ratio 
 
95% CI 
 
P-Value 
CC+CT 132.5 76.5 
0.13 0.01 – 2.40 0.1717 
TT 6.5 0.5 
CC 96 51 
1.12 0.61 – 2.04 0.7104 
CT+TT 42 25 
rs3132468 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
CC+CT 52 33 
0.78 0.44 – 1.38 0.3892 
TT 87 43 
CC 5 3 
0.91 0.21 – 3.91 0.8968 
CT+TT 134 73 
rs3213545 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
AA+AG 60 30 
1.18 0.67 – 2.09 0.5702 
GG 78 46 
AA 7 3 
1.30 0.33 – 5.18 0.7097 
GA+GG 131 73 
rs3737399 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds Ratio 95% CI P-Value 
CC+CT 100 60 
0.81 0.40 – 1.62 0.5439 TT 
31 15 
CC 100 59 
0.87 0.44 – 1.73 0.7014 
CT+TT 31 16 
rs3911403 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever (DF) 
Odds 
Ratio 
95% CI P-Value 
AA+A 27 20 
0.71 0.37 – 1.39 0.3201 
TT 104 55 
AA 5 1 
2.94 0.34 – 25.62 0.3297 TA+TT 126 74 
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rs4251580 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever 
(DF) 
Odds 
Ratio 
95% CI P-Value 
CC+CT 122.5 71.5 
0.34 0.02 – 7.24 0.4913 
TT 2.5 0.5 
CC 101 51 
1.72 0.87 – 3.42 0.1212 CT+TT 23 20 
rs486907 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever 
(DF) 
Odds 
Ratio 
95% CI P-Value 
CC+CT 121 67 
1.05 0.40 – 2.80 0.9169 
TT 12 7 
CC 58 33 
0.96 0.54 – 1.70 0.8911 
CT+TT 75 41 
rs606231248 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever 
(DF) 
Odds 
Ratio 
95% CI P-Value 
AA+AG 48 21 
1.42 0.76 – 2.64 0.2666 
GG 82 51 
AA 14 5 
1.62 0.33 – 4.69 0.3761 
GA+GG 116 67 
rs2072138 
 
Severe 
Dengue 
(CD+DHF) 
Dengue 
Fever 
(DF) 
Odds 
Ratio 
95% CI P-Value 
AA+CA 11 3 
2.13 0.58 – 7.86 0.2666 
CC+GG+GC 131 76 
GG+GC 64 44 
0.65 0.38 – 1.14 0.1308 
AA+CA+CC 78 35 
CC+CA+GC 125 70 
0.95 0.40 – 2.23 0.8981 
AA+GG 17 9 
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